CLSD | tickerfilter.com

Fundamental analysis

43%

Profitability 43%

Dept financing 25%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.06%

1 Month

-3.92%

3 Months

-13.11%

6 Months

-42.89%

1 Year

-34.47%

2 Year

-31.83%

Key data

Stock price

$0.85

P/E Ratio

0.00

DAY RANGE

$0.82 - $0.94

EPS

-$0.47

52 WEEK RANGE

$0.77 - $1.65

52 WEEK CHANGE

-$34.47

MARKET CAP

72.051 M

YIELD

N/A

SHARES OUTSTANDING

74.731 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.45

PUBLIC FLOAT

AVERAGE 10 VOLUME

$150,418

AVERAGE 30 VOLUME

$162,447

Company detail

CEO: George M. Lasezkay
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.

CLSD - Clearside Biomedical, Inc.